Cuprina Holdings (Cayman) Ltd (CUPR) Earnings

Cuprina Holdings (Cayman) Ltd. engages in the manufacturing, sale, and supply of medical devices to manage and accelerate healing and closure of chronic wounds. The company employs 10 full-time employees The company went IPO on 2025-04-10. Its segments include Maggot Debridement Therapy Product (MDT) and Cosmeceutical Product. The company manufactures and distributes a line of medical grade sterile blowfly larvae bio-dressing products marketed under the MEDIFLY brand name, or the MEDIFLY products. The MEDIFLY products are used as a biological debridement tool for chronic wounds, in a procedure known as MDT, which is an effective alternative to surgical debridement. The company has two lines of chronic wound care products in its pipeline, such as Collagen dressings, including sponges, particles and hydrogels utilizing bullfrog collagen derived from the valorization of abattoir waste streams of American bullfrogs (Lithobates catesbeianus) and products utilizing medical leeches for wound treatment.